Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats

Show other versions (1)

Background: Presently cancer is second major cause of death in India. Doxorubicin, an anthracycline is frequently used to treat various human malignancies but at same time its use is warranted with irreversible cardiomyopathy. Ayurveda, ancient science of Medicine has advocated various herbal drugs...

Full description

Bibliographic Details
Published in:	Indian Journal of Ayurveda and Integrative Medicine KLEU
Main Authors:	Shrutika Subhash Karoshi, Kolume Dugeppa Govindappa, Kalanghot Padmanabhan Skandhan
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2019-01-01
Subjects:	cardio-toxicity sindhuvaradi agada nirgundi doxorubicin cancer.
Online Access:	http://www.ijaim.in/article.asp?issn=2772-6010;year=2019;volume=1;issue=1;spage=39;epage=42;aulast=Karoshi

Similar Items

Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats
by: Shrutika Subhash Karoshi, et al.
Published: (2018-01-01)

Effect of an Ayurveda antidote Dooshivishari Agada in carboplatin induced myelosuppression in Male Wistar rats
by: Santosh F. Patil, et al.
Published: (2022-07-01)

Comparative Efficacy of Therapeutic Ultrasound and Nirgundi Oil Phonophoresis on Temporomandibular Joint Disorders: An Observational Study
by: Nishanthi Raja, et al.
Published: (2024-10-01)

Comparative Evaluation of Polyphenol Contents and Antioxidant Activities between Ethanol Extracts of Vitex negundo and Vitex trifolia L. Leaves by Different Methods
by: Sarla Saklani, et al.
Published: (2017-09-01)

Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
by: Manrose Singh, et al.
Published: (2022-01-01)

The Witching Body: Ontology and Physicality of the Witch
by: Devereux Katherine R.
Published: (2022-06-01)

5-Oxoproline prevents doxorubicin-induced cardiotoxicity and tumor growth
by: Xinning Guo, et al.
Published: (2025-09-01)

Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
by: Anchit Bhagat, et al.
Published: (2022-08-01)

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future
by: A. M. Chaulin, et al.
Published: (2022-03-01)

The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases
by: Sofia Reis Brandão, et al.
Published: (2023-11-01)

Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by: Iacob-Daniel Goje, et al.
Published: (2025-05-01)

Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity
by: Eglė Čiburienė, et al.
Published: (2022-04-01)

The broad spectrum of cardiotoxicities from immunotherapies
by: Martina Iengo, et al.
Published: (2023-09-01)

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity
by: Dong-Woo Kang, et al.
Published: (2022-01-01)

Doxorubicin-related effects on cardiorespiratory function and body composition
by: Ashley J. Smuder
Published: (2024-02-01)

Investigation of some chemotherapy drugs induce cardiotoxicity
by: Asia A. Mahdi, et al.
Published: (2025-08-01)

Induction of autophagy has protective roles in imatinib-induced cardiotoxicity
by: Miyuki Kobara, et al.
Published: (2021-01-01)

Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells
by: Chrysa Koukorava, et al.
Published: (2024-07-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Enhancing nurse competence in early recognition of cardiotoxicity
by: Jeff Kolbus, et al.
Published: (2024-09-01)

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
by: Dong R, et al.
Published: (2022-09-01)

Association between Statin Use and Chemotherapy-Induced Cardiotoxicity: A Meta-Analysis
by: Vikash Jaiswal, et al.
Published: (2024-03-01)

In the Heart of Cardio-Oncology: The Targets and Biomarkers of Cardiotoxicity in Anticancer Drugs
by: Vera Marisa Costa
Published: (2022-11-01)

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
by: Yichuan Jiang, et al.
Published: (2023-05-01)

Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity
by: Lauren A. Ling, et al.
Published: (2025-05-01)

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
by: V. Quagliariello, et al.
Published: (2024-05-01)

ICIs-Related Cardiotoxicity in Different Types of Cancer
by: Mei Dong, et al.
Published: (2022-06-01)

Cardiotoxicity and Chemotherapy—The Role of Precision Medicine
by: Thyla Viswanathan, et al.
Published: (2021-12-01)

Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity
by: Luyao Ma, et al.
Published: (2025-10-01)

Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review
by: Jarosław Szponar, et al.
Published: (2024-07-01)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
by: Neha Bansal, et al.
Published: (2019-12-01)

Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies
by: Adelaide Iervolino, et al.
Published: (2022-12-01)

Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
by: Carmelita Abrahams, et al.
Published: (2022-09-01)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
by: Ru Chen, et al.
Published: (2022-11-01)

Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
by: Anthony F. Yu, et al.
Published: (2023-03-01)

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
by: Marc Hilmi, et al.
Published: (2020-10-01)

Current Evidence on the Benefit of Exercise in Cancer Patients: Effects on Cardiovascular Mortality, Cardiotoxicity, and Quality of Life
by: Núria Coma, et al.
Published: (2023-06-01)

Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology
by: Hasan Kobat, et al.
Published: (2021-02-01)

Cardiological parameters predict mortality and cardiotoxicity in oncological patients
by: Sebastian W. Romann, et al.
Published: (2024-02-01)

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey
by: Massimiliano Camilli, et al.
Published: (2023-08-01)